|
EQS-News: Eckert & Ziegler SE / Key word(s): Annual Results Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023 22.03.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, March 22, 2024 – Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of € 246.1 million in the 2023 financial year. Compared to the previous year, sales increased by € 23.8 million or 11%. EBIT from continuing operations before special items reached € 46.9 million. Net profit for the year amounted to € 26.3 million corresponding to earnings per share of € 1.26. In the Medical segment, sales rose by € 24.3 million or 27% to € 115.2 million compared to the previous year. The increase in sales was driven in particular by strong demand for radiopharmaceuticals. At € 130.9 million, sales in the Isotope Products segment remained at the previous year’s level (€ 131.4 million). For the 2024 financial year, the Executive Board expects sales of just under € 265 million and EBIT before special items from continuing operations of around € 50 million. The full 2023 financial statements can be found here: About Eckert & Ziegler. For enquiries please contact: 22.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Infant face preference linked to genetics
Whether infants at five months of age look mostly at faces or non-social objects such as cars or mobile phones is largely determined by genes.
November 27, 2023